Treatment of venous malformations with sclerosant in microfoam form

被引:140
|
作者
Cabrera, J
Cabrera, J
García-Olmedo, A
Redondo, P
机构
[1] Univ Navarra Clin, Dept Dermatol, Pamplona 31080, Spain
[2] Vasc Surg Clin, Granada, Spain
关键词
D O I
10.1001/archderm.139.11.1409
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Treatment of congenital venous malformations poses a major clinical challenge. Surgery is difficult and frequently unsuccessful, radiological intervention with embolization has an ill-defined role, and conventional sclerotherapy has little to offer. Objective: To evaluate the efficacy and safety of sclerosant in microfoam form in treating congenital venous malformations. Design: A retrospective study of medical records, pretreatment and posttreatment color photographs, echo-Doppler ultrasonographic results, and/or magnetic resonance imaging in patients with congenital vascular malformations of venous predominance. Follow-up ranged from 6 to 103 months (mean, 30 months). Setting: Private vascular surgery clinic in Granada, Spain, and dermatology department at a university hospital in Pamplona. Patients: The study population comprised 50 patients, 19 with limited venous malformations, 16 with infiltrating venous malformations, and 15 with Klippel-Trenaunay syndrome. Intervention: Percutaneous sclerotherapy by direct injection of 0.25% to 4% polidocanol microfoam under duplex ultrasonographic guidance. The number of sessions varied between 1 and 46 (mean, 12 sessions). Main Outcome Measure: The primary efficacy end point was defined as a reduction in size after completion of the treatment. Results: Sclerosis therapy with polidocanol microfoam was judged beneficial in 46 (92%) of the 50 patients. Among the 46 responders, 18 showed disappearance of treated malformations, 15 showed a reduction in malformation size of more than 50%, and 13 showed a reduction in malformation size of 50% or less. Of the 39 patients who presented with pain, the pain disappeared in 25 and was reduced in 14. No major adverse effects were reported by any patient. There were 4 cases of transient skin pigmentation and 3 cases of skin necrosis. Conclusions: Color echo-Doppler ultrasonography-guided sclerotherapy with polidocanol microfoam was effective in 46 (92%) of the patients. The technique is delivered on a strictly ambulatory basis and has proved simple and innocuous. The quality and durability of the outcome make this novel procedure the treatment of choice in the care of patients with congenital venous malformations.
引用
收藏
页码:1409 / 1416
页数:8
相关论文
共 50 条
  • [1] TREATMENT of CONGENITAL VENOUS MALFORMATIONS by SCLEROSANTS in MICROFOAM FORM
    Cabrera, J.
    Martinez de la Cuesta, A.
    Sierra, A.
    Redondo, P.
    [J]. PHLEBOLOGIE-ANNALES VASCULAIRES, 2008, 61 (03): : 290 - 296
  • [2] TREATMENT of CONGENITAL VENOUS MALFORMATIONS by SCLEROSANTS in MICROFOAM FORM COMMENTRY
    Gobin, J. P.
    [J]. PHLEBOLOGIE-ANNALES VASCULAIRES, 2008, 61 (03): : 296 - 296
  • [3] Treatment of varicose long saphenous veins with sclerosant in microfoam form:: Long-term outcomes
    Cabrera, J
    Cabrera, J
    García-Olmedo, MA
    [J]. PHLEBOLOGY, 2000, 15 (01) : 19 - 23
  • [4] Polidocanol for endovenous microfoam sclerosant therapy
    Eckmann, David M.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (12) : 1919 - 1927
  • [5] Sclerotherapy with polidocanol microfoam in head and neck venous and lymphatic malformations
    De Corso, Eugenio
    Cina, Alessandro
    Salonna, Giampiero
    Di Cintio, Giovanni
    Gaudino, Simona
    Panfili, Marco
    Colosimo, Cesare
    Paludetti, Gaetano
    [J]. ACTA OTORHINOLARYNGOLOGICA ITALICA, 2022, 42 (02) : 116 - 125
  • [6] Venous disorders: treatment with sclerosant foam
    Bergan, J
    Pascarella, L
    Mekenas, L
    [J]. JOURNAL OF CARDIOVASCULAR SURGERY, 2006, 47 (01): : 9 - 18
  • [7] Ethanol foam: a novel type of foam sclerosant for treating venous malformations
    Zhang, Han-Shu
    Liu, Yi-Ran
    Liu, Shao-Hua
    [J]. FRONTIERS IN NEUROLOGY, 2024, 15
  • [8] Microvascular embolization following polidocanol microfoam sclerosant administration
    Eckmann, DM
    Kobayashi, S
    Min, L
    [J]. DERMATOLOGIC SURGERY, 2005, 31 (06) : 636 - 643
  • [9] Venous ansgiomata: Treatment with sclerosant foam
    Pascarella, L
    Bergan, JJ
    Yamada, C
    Mekenas, L
    [J]. ANNALS OF VASCULAR SURGERY, 2005, 19 (04) : 457 - 464
  • [10] Microfoam treatment of Klippel-Trenaunay syndrome and vascular malformations
    Redondo, Pedro
    Cabrera, Juan
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (02) : 355 - 356